The study, published in The Lancet, evaluated the pharmacokinetics, safety and tolerability of two intramuscular formations of lenacapavir in participants ages 18-55 without HIV.
Results showed that a single 5,000-milligram intramuscular dose maintained drug concentrations above levels associated with efficacy in previous phase 3 trials for at least 56 weeks.
Compared to the currently studied biannual subcutaneous version, the annual formulation achieved higher plasma concentrations, suggesting potential for long-lasting HIV prevention.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.